The Oncology Institute, Inc.
TOI$5.13
$-1.26 (-19.72%)-19.72%
ClosedLoading chart...
IndexN/A
Market Cap0.51B
Enterprise ValueN/A
Income$-0.02B
Sales$0.10B
EmployeesN/A
P/E-14.25
P/SN/A
P/BN/A
P/CN/A
EV/EBITDAN/A
EV/SalesN/A
EPS (ttm)-0.36
EarningsN/A
Gross MarginN/A
Oper. MarginN/A
Profit MarginN/A
Volume1.21M
Shs Outstand0.10B
Change-19.72%
Dividend Est.N/A
Dividend Ex-DateN/A
Perf YTDN/A
Perf YearN/A
Perf 3YN/A
Perf 5YN/A
Perf 10YN/A
IPON/A
| Metric | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|
| Revenue | $393.41M | $324.24M | $252.48M | $203.00M | $187.51M | $155.41M | $113.16M |
| Cost of Revenue | $339.42M | $264.67M | $200.39M | $162.16M | $150.64M | $125.46M | $86.88M |
| Gross Profit | $54.00M | $59.57M | $52.09M | $40.85M | $36.88M | $29.94M | $26.28M |
| Gross Margin | 13.73% | 18.37% | 20.63% | 20.12% | 19.67% | 19.27% | 23.23% |
| Operating Expenses | $114.11M | $136.59M | $134.04M | $86.71M | $45.07M | $32.59M | $21.49M |
| Operating Income | $-60.12M | $-77.02M | $-81.95M | $-45.86M | $-8.20M | $-2.64M | $4.79M |
| Operating Margin | -15.28% | -23.75% | -32.46% | -22.59% | -4.37% | -1.70% | 4.23% |
| Net Income | $-64.66M | $-83.07M | $152.00K | $-10.93M | $-14.32M | $-4.02M | $3.95M |
| Net Margin | -16.44% | -25.62% | 0.06% | -5.38% | -7.64% | -2.59% | 3.49% |
| EPS (Basic) | $-0.71 | $-0.92 | $0.00 | $-0.16 | $-0.24 | $-0.06 | $0.14 |
| EBITDA | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Stock Option Compensation Expense | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Price To Earnings Ratio | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Price To Sales Ratio | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Shares Outstanding | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Market Capitalization | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Metric | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|
| Cash & Short Term Investments | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Short Term Receivables | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Inventories | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Other Current Assets | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Current Assets | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Net Property, Plant & Equipment | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Investments and Advances | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Long-Term Note Receivable | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Intangible Assets | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Deferred Tax Assets | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Other Assets | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Assets | $172.72M | $209.24M | $261.67M | $203.44M | $65.69M | $59.52M | $0.00 |
| Short Term Debt Incl. Current Port. of LT Debt | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Accounts Payable | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Income Tax Payable | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Other Current Liabilities | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Current Liabilities | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Long Term Debt | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Provision for Risks Charges | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Deferred Tax Liabilities | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Other Liabilities | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Liabilities | $169.13M | $152.22M | $138.49M | $99.28M | $37.59M | $17.30M | $0.00 |
| Non-Equity Reserves | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Preferred Stock - Carrying Value | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Common Equity | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Shareholders Equity | $3.59M | $57.02M | $123.17M | $104.16M | $28.10M | $42.22M | $0.00 |
| Accumulated Minority Interest | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Equity | $3.59M | $57.02M | $123.17M | $104.16M | $28.10M | $42.22M | $0.00 |
| Total Liabilities & Stockholders Equity | $172.72M | $209.24M | $261.67M | $203.44M | $65.69M | $59.52M | $0.00 |
| Book Value Per Share | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Tangible Book Value Per Share | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Full-Time Employees | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Price to Book Ratio | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Return on Assets | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Return on Equity | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Return on Invested Capital | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Quick Ratio | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Current Ratio | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Metric | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|
| Net Income | $-64.66M | $-83.07M | $152.00K | $-10.93M | $-14.32M | $-4.02M | $3.95M |
| Depreciation | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Other Funds (Non Cash) | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Funds from Operations | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Extraordinary Item | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Changes in Working Capital | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Income Taxes Payable | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Cash from Operating Activities | $-26.54M | $-36.31M | $-61.76M | $-32.68M | $508.00K | $3.62M | $5.64M |
| Capital Expenditures | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Net Assets From Acquisitions | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Sale of Fixed Assets and Businesses | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Purchase or Sale of Investments | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Purchase of Investments | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Sale Or Maturity of Investments | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Other Uses | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Other Sources | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Cash from Investing Activities | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Cash Dividends Paid | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Change in Capital Stock | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Repurchase of Common Pref Stock | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Sale of Common Pref Stock | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Proceeds from Stock Options | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Issuance or Reduction of Debt, Net | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Change in Long Term Debt | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Issuance of Long Term Debt | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Reduction of Long Term Debt | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Net Financing Active Other Cash Flow | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Other Financing Activities Uses | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Cash from Financing Activities | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Exchange Rate Effect | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Net Change in Cash | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Free Cash Flow | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Preferred Dividends (Cash Flow) | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Price to Free Cash Flow | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
Company coverage
Latest news
Oncology Institute Q2 Earnings Call Highlightsmarketbeat.com The Oncology Institute Rebrands as Starling Oncologyglobenewswire.com The Oncology Institute Announces Second Quarter 2026 Earnings Release Date and Conference Callglobenewswire.com Best Cheap Stocks Under $10 to Buy Now in Julyzacks.com The Oncology Institute Completes Strategic Refinancing with OrbiMed, Repaying the Outstanding $86 Million Deerfield Convertible Note, Strengthening its Balance Sheet, and Improving Liquidityglobenewswire.com 2 More Stocks to Buy for the AI Convergenceinvestorplace.com The Oncology Institute (TOI) Soars 5.3%: Is Further Upside Left in the Stock?zacks.com 3 Stocks to Buy for the AI Convergenceinvestorplace.com
Show 12 more stories
How Much Upside is Left in The Oncology Institute (TOI)? Wall Street Analysts Think 38.07%zacks.com Oncology Institute To Rally Over 64%? Here Are 10 Top Analyst Forecasts For Mondaybenzinga.com Topicus.com Inc. Announces a Revised Proposal to Acquire ReadyTechglobenewswire.com The Oncology Institute Chief Medical Officer to Speak on Value-Based Specialty Care at APG Spring Conferenceglobenewswire.com Topicus.com Inc. (TOI:CA) Shareholder/Analyst Call Prepared Remarks Transcriptseekingalpha.com The Oncology Institute to Participate in B. Riley Securities Institutional Investor Conferenceglobenewswire.com Constellation Software Inc., Topicus.com Inc. and Lumine Group Inc. Announce Update to Schedule for Annual Meetingsglobenewswire.com Oncology Institute Q1 Earnings Call Highlightsmarketbeat.com The Oncology Institute, Inc. (TOI) Reports Q1 Loss, Beats Revenue Estimateszacks.com The Oncology Institute Reports First Quarter 2026 Financial Resultsglobenewswire.com Constellation Software Inc. and Topicus.Com Inc. Announce Results for Topicus.com Inc. for the First Quarter Ended March 31, 2026globenewswire.com The Oncology Institute Announces First Quarter 2026 Earnings Release Date and Conference Callglobenewswire.com
Insider Trading
View AllInsider
Type
Shares
Price
Value
Date
Company
About the company
The Oncology Institute (TOI) is a specialized healthcare provider delivering a full range of medical oncology services throughout the United States. Its comprehensive offerings include direct physician care, integrated on-site infusion and medication dispensing facilities, and advanced clinical trial management. The institute also provides radiation therapy, specialized outpatient programs for stem cell transplants and transfusions, and robust patient support services. Furthermore, TOI is actively involved in operating palliative care initiatives and overseeing clinical trials. These services are specifically designed to meet the needs of adult and senior cancer patients. The company maintains a significant operational footprint with 67 clinic locations. The Oncology Institute was established in 2007 and is headquartered in Cerritos, California.
Discover more
You may be interested in